Tag: Elucid

Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Financial by 0 comments

BOSTON, June 22, 2022 /PRNewswire/ — Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round.  The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, […]

Continue Reading →

Elucid Announces American Medical Association (AMA) Instates CPT Code for Lipid-Rich Necrotic Core Quantification to Assess Atherosclerotic Plaque Stability

Coronary/Structural Heart by 0 comments

Quantification of the structure and composition of the vessel wall and assessment of lipid-rich necrotic core plaque (CPT 0710T-0713T) BOSTON–(BUSINESS WIRE)–Elucid, a Boston-based medical technology company harnessing scientific imaging and artificial intelligence to enable the precise diagnosis and treatment of […]

Continue Reading →

Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography

Coronary/Structural Heart by 0 comments

Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its […]

Continue Reading →

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers

Coronary/Structural Heart by 0 comments

Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced that first author […]

Continue Reading →

Study Confirms Elucid’s AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care

Coronary/Structural Heart by 0 comments

BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced today the publication of new clinical data in the International Journal of Cardiology. The study, entitled “Coronary plaque assessment of Vasodilative capacity by CT angiography effectively […]

Continue Reading →
1 2